business
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
Key takeaways
- The estimated value of the trade was $11.96 million based on the average closing price for the first quarter of 2026.
- This was a new position for Patient Square Capital LP and represented 2.68% of its reportable AUM at quarter-end
- NASDAQ: ROIV: $226,199,502 (40.1% of AUM)
Cory Renauer, The Motley Fool Sat, May 16, 2026 at 9:29 PM GMT+7 3 min read What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics (NASDAQ:NKTR). The estimated value of the trade was $11.96 million based on the average closing price for the first quarter of 2026. The quarter-end value of this new position stood at $15.11 million, reflecting the valuation shift, including price movement.
This was a new position for Patient Square Capital LP and represented 2.68% of its reportable AUM at quarter-end
NASDAQ: ROIV: $226,199,502 (40.1% of AUM)
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop